HER2-Low BC Incidence, Clinical Features, and Outcomes
Human epidermal growth factor receptor 2 (HER2)-low is a newly defined subset of HER2-negative breast cancer (BC) that may include up to 50% to 60% of patients previously classified as HER2-negative. Tumors are labeled as HER2-negative because they do not overexpress the HER2 protein; however, HER2-low tumors contain low levels of HER2 protein on their surface. Read more.

Racial Disparities in BC Associated With Poorer Outcomes
Racial disparities in healthcare delivery have been associated with poorer outcomes in persons of color compared with their white counterparts. Data are emerging that factors affecting social determinants of health and racial disparities can adversely impact tumor biology and survival in breast cancer (BC). Racial disparities in BC can also affect treatment patterns and treatment-related adverse events. Read more.

Examining Bevacizumab Use and Associated Adverse Events
Although bevacizumab’s breast cancer (BC) indication was withdrawn by the FDA in 2011, the National Comprehensive Cancer Network guidelines on BC indicated that the addition of bevacizumab to first- or second-line chemotherapy agents modestly improves time to progression and response rates but not overall survival or quality of life of patients with metastatic BC. Learn more about the safety profile of bevacizumab.